Hudson Bay Capital Management LP Unicycive Therapeutics, Inc. Transaction History
Hudson Bay Capital Management LP
- $28.9 Billion
- Q1 2025
A detailed history of Hudson Bay Capital Management LP transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 14,840 shares of UNCY stock, worth $8,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,840Holding current value
$8,755% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
59.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA11.4MShares$6.71 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$6.48 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.9 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$5.54 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3 Million0.56% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.88M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...